DTC — Defence Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- CA$56.92m
- CA$58.08m
Annual balance sheet for Defence Therapeutics, fiscal year end - June 30th, CAD millions except per share, conversion factor applied.
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 0.001 | 1.87 | 5.45 | 0.507 | 2.79 |
| Net Total Receivables | — | — | 0.072 | 0.028 | 0.15 |
| Prepaid Expenses | |||||
| Total Current Assets | 0.008 | 1.87 | 5.56 | 0.674 | 3.43 |
| Net Property, Plant And Equipment | — | — | — | — | 0.059 |
| Net Intangible Assets | |||||
| Total Assets | 0.008 | 1.91 | 5.61 | 0.72 | 3.53 |
| Payable / Accrued | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 0.008 | 0.048 | 0.122 | 1.11 | 0.22 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 0.008 | 0.048 | 0.122 | 1.11 | 1.97 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -0 | 1.86 | 5.49 | -0.388 | 1.57 |
| Total Liabilities & Shareholders' Equity | 0.008 | 1.91 | 5.61 | 0.72 | 3.53 |
| Total Common Shares Outstanding |